“Biomanufacturing has shifted focus from just being efficient to staying ahead of the curve”
In an exclusive interview, Sachin Joshi, Managing Director & Founder, PharmNXT Biotech shares insights on the company’s focus on innovation, key product offerings, upcoming initiatives, sustainability and future plans.
PharmNXT Biotech focuses on advanced bioprocessing solutions. What key industry challenges are you addressing?
At PharmNXT Biotech, we are tackling one of the most pressing cost drivers in biologics and generics manufacturing—the exorbitant cost of raw materials, exacerbated by India’s 90% import dependency on critical consumables, APIs and key starting materials. This reliance inflates production costs, extends lead times, and creates vulnerabilities in supply chain resilience. Our approach is two-pronged: first, we have set up India’s first integrated indigenous state-of-the-art facility in Pune to produce high-quality bioprocessing consumables at par with global standards. This not only reduces costs but also strengthens India’s supply chain independence. Second, we recognise that cost efficiency is not just about localized production; it is also about customization and scalability; we cater to the precise needs of our clients in terms of specifications.
Global companies often impose minimum order quantities (MOQs) and associated costs, but we produce materials tailored to individual orders, maximizing shelf life and minimizing wastage during transit. PharmNXT Biotech is building a robust ecosystem where India is not a passive consumer of biotech innovation but an active producer, setting new global benchmarks in affordability, accessibility, and quality.
Your major product offerings and latest innovations to enhance biomanufacturing efficiency?
Biomanufacturing has shifted focus from just being efficient to staying ahead of the curve. The industry is advancing rapidly, and the true driving forces are innovation, the ability to operate independently, and expanding operations to a larger scale.
First, our single-use consumables—including storage bags, mixer bags, powder bags, manifolds, assemblies, and liners—are produced in our globally certified Pune facility, eliminating costly imports while ensuring international-grade quality. Second, our hardware vertical delivers cutting-edge bioprocessing equipment, from stainless-steel mixers and storage vessels to filtration skids, chromatography systems, inline buffer preparation systems, and viral filtration units—all manufactured in India to drive down costs and lead times. Third, our global partnerships are bringing high-quality chromatography resins and precise freezing technologies to India, smoothly integrating them into end-to-end production workflows. By producing locally and tapping into global expertise, we are making biomanufacturing faster, leaner, and more accessible. Our mission is clear: position India as a global leader in biopharmaceutical innovation while expanding access to life-saving therapies worldwide.
The company has made significant strides in producing Single-Use products and containment solutions. What inspired the shift to in-house manufacturing, and how does it give you a competitive edge in the global market?
Our shift to in-house manufacturing of single-use products and containment solutions was driven by firsthand experience in the biopharma industry. Having worked with global biopharma leaders, our team has witnessed bottlenecks, cost pressures, and supply chain vulnerabilities stemming from India’s growing sector. We built PharmNXT Biotech to solve these challenges, ensuring that India is not just a participant but a global leader in biomanufacturing innovation.
Our 20,000 sq.ft. Ekuse facility, fully operational in just nine months, produces 30,000 single-use bags per month while maintaining global quality standards. Designed for scalability, it can triple its capacity to meet rising demand. This gives us a strong competitive edge, allowing us to offer just-in-time solutions, reduce costs, and eliminate long lead times—a challenge global suppliers often struggle with.
Further solidifying our competitive advantage, PharmNXT Biotech has established a strong foothold in 12 countries, including ASEAN, the U.S., and Europe, with offices in Singapore and South Korea and partnerships with leading players in the U.S. and Europe. We mix local manufacturing with global expertise, introducing advanced technology and scalable bioprocessing innovations to India. This combination helps us deliver high-quality, affordable, and fully integrated bioprocessing solutions. As a result, we have become the preferred choice for the biopharma companies.
“In FY26, our primary objectives include scaling our manufacturing capabilities, strengthening co-innovation initiatives, and expanding our product portfolio.”
Sustainability is a growing focus in biopharma. What steps is PharmaNXT taking to integrate eco-friendly practices in its manufacturing processes, especially for Single-Use products?
PharmNXT Biotech’s Single-Use solutions support sustainability goals by reducing water wastage, chemical use, and resource consumption. Our products are designed to minimize waste, optimize clean-room space, and enhance operational efficiency. For example, the NXTbin container’s cylindrical design maximizes storage capacity and workflow efficiency, while its 100% drainability prevents product loss. Similarly, all our single-use consumables eliminate the need for energy-intensive cleaning and sterilization, further reducing water and chemical consumption. Additionally, localized production lowers transit times and reduces inventory wastage for customers through just-in-time logistics. PharmNXT Biotech is driving eco-conscious, high-efficiency bioprocessing solutions that align with global sustainability standards by integrating waste reduction, process efficiency, and sustainable material use.
How has been the company’s financial performance in FY25 and your revenue target for FY 26?
PharmNXT Biotech has demonstrated strong financial growth in FY25, driven by expanding global partnerships, increased demand for single-use solutions, and enhanced production capacity. As we look ahead to FY26, we are targeting multiple revenue growth, supported by strategic investments in capacity expansion, product innovation, and new market penetration.
What are your key goals in FY26? Any plans to expand your global footprint?
In FY26, our primary objectives include scaling our manufacturing capabilities, strengthening co-innovation initiatives, and expanding our product portfolio to address next-generation bioprocessing needs. With a strong foothold in 12 countries, including ASEAN, the U.S., and Europe, along with offices in Singapore and South Korea, we plan to deepen our global presence by forging new partnerships in key biopharma markets.
Additionally, we are committed to enhancing automation and developing high-performance solutions tailored for biosimilars, mRNA, and cell and gene therapy production.
*This interview was first published in the April 2025 edition of BioVoice eMagazine.
The post “Biomanufacturing has shifted focus from just being efficient to staying ahead of the curve” appeared first on BioVoiceNews.
News